Matthew Gavidia

Matthew is an associate editor of The American Journal of Managed Care® (AJMC®). He has been working on AJMC® since 2019 after receiving his Bachelor's degree at Rutgers University–New Brunswick in journalism and economics.


High OOP Costs for Treatment of Psoriatic Disease Found in Medicare Beneficiaries

September 15, 2021

Medicare beneficiaries with psoriasis and psoriatic arthritis were found to pay high annual out-of-pocket (OOP) costs for treatment, which researchers attributed to rising drug prices and reliance on co-insurance for patient cost-sharing.

Comorbid Ophthalmic, Systemic Conditions Linked With Higher Risk of Dementia

September 15, 2021

People with both ophthalmic and systemic conditions were found to be at higher risk of dementia compared with those with only 1 such condition. Some ophthalmic conditions—age-related macular degeneration, cataract, and diabetes-related eye disease—also increased risk on their own.

Spotlighting Social, Emotional Needs in Underserved Populations With Cancer

September 14, 2021

Psychological and emotional needs specific to populations with cancer are often overlooked in clinical research, including those of adolescents, young adults, immigrants, and people of lower socioeconomic status.

Alpha-Glucosidase Inhibitor Use in Type 2 Diabetes Linked With Increased Psoriatic Disease Risk

September 11, 2021

Discontinued use and high dosage of alpha-glucosidase inhibitors in combination with metformin was shown to increase risk of psoriasis and psoriatic arthritis in patients with type 2 diabetes compared with those given only metformin.

Phase 2 Study Finds Tildrakizumab Effective for PsA Manifestations

September 09, 2021

Findings of a phase 2b study indicated that use of tildrakizumab was associated with significant improvements in joint and skin manifestations of patients with psoriatic arthritis (PsA), although improvement in symptoms of dactylitis and enthesitis were not observed.